KRAS mutations in plasma EVs identified in ≈80%–85% of patients with locally advanced and metastatic pancreatic ductal adenocarcinoma (PDAC) may be a broad predictor for cancer‐screening.[101] Using next‐generation deep sequencing to analyze the plasma EV‐miRNA expression profiles of patients with Alzheimer's disease (AD), an AD‐specific 16‐miRNA signature is identified to be able to increase the sensitivity and specificity of AD prediction to 87% and 77%, respectively.[102]. This evidence concerns the gene KRAS and Alzheimer disease.